Objective To assess the benefits of intrauterine infusion of Granulocyte Colony Stimulating Factor (G-CSF) to enhance pregnancy outcomes for patients with a history of recurrent miscarriage (RM) and recurrent implantation failure (RIF). Design Retrospective cohort study and systemic reviews without meta-data analysis. Settings Fakih IVF center in Abu Dhabi, UAE. Patients A total of 19 patients at Fakih IVF Center, Abu Dhabi, UAE were selected, who consulted the center from April 2023 till January 2024, with an age range of 27-44 years old and a Body Mass Index (BMI) ranging from 24.6-38.5. Intervention Intrauterine infusion of Filgrastim (G-CSF) 300mcg/5ml was infused for 5 days pre-embryo transfer. After the endometrial thickness of 7 mm was achieved, patients received standard luteal support, and the outcomes were assessed based on biochemical and clinical pregnancy, miscarriage, and ongoing viable pregnancy. All the patients had a single embryo transferred. Results Out of the 19 patients, eight patients achieved successful ongoing pregnancies (60%); two patients’ procedures were canceled due to bleeding, five had implantation failure, two achieved biochemical pregnancies, and two had first-trimester miscarriages. None of the patients developed any side effects. Conclusion Intrauterine G-CSF infusion may have a beneficial impact on patients with a history of implantation failure or miscarriage. However, further research is required to validate these results and elucidate the underlying mechanisms of action of G-CSF in improving IVF success rates by enhancing endometrial receptivity. Such research may contribute to the development of novel therapeutic strategies for RM and RIF patients.
No takes yet. Share an insight, caveat, or question.
Alhmoudi et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: